ライフサイエンスコーパス: virus disease

1 EBOV-GP vaccine in persons at risk for Ebola virus disease.

2 preventive vaccines to protect against Zika virus disease.

3 ulate the inflammatory response during Ebola virus disease.

4 odies meeting the case definitions for Ebola virus disease.

5 bola virus disease, Lassa fever, and Marburg virus disease.

6 interferons (IFNs) in animal models of Ebola virus disease.

7 the prevention of laboratory confirmed Ebola virus disease.

8 the confirmation of the first case of Ebola virus disease.

9 clinical development for treatment of Ebola virus disease.

10 cted non-human primates (NHPs) against Ebola virus disease.

11 stexposure prophylaxis; none developed Ebola virus disease.

12 ases, such as Zika virus infection and Ebola virus disease.

13 (TEG) in the management of 2 cases of Ebola virus disease.

14 rst licensed vaccine for prevention of Ebola virus disease.

15 elae seen in West African survivors of Ebola virus disease.

16 safely provide care for patients with Ebola virus disease.

17 ae persist for more than 2 years after Ebola virus disease.

18 s are the most common complications of Ebola virus disease.

19 de insight into the pathophysiology of Ebola virus disease.

20 with increased likelihood of confirmed Ebola virus disease.

21 ly used hollow-bore needles, developed Ebola virus disease.

22 and virological follow-up of a case of Ebola virus disease.

23 ort, and investigational therapies for Ebola virus disease.

24 d a wide range of diagnoses other than Ebola virus disease.

25 clinical characteristic for confirmed Ebola virus disease.

26 may contribute to the severity of influenza virus disease.

27 uld play a role in vaccination against Ebola virus disease.

28 o inflammation during human immunodeficiency virus disease.

29 accine (FILORAB3) to protect against Marburg virus disease.

30 or the efficient monitoring and treatment of virus diseases.

31 approved drugs to treat both Lassa and Ebola virus diseases.

32 ical signs and symptoms associated with Zika virus disease, 133 (94%) children had rash, 104 (74%) fe

33 The current health crisis of corona virus disease 2019 (COVID-19) highlights the urgent need

34 ical characteristics of patients with Corona Virus Disease 2019 (COVID-19) in Beijing.

35 The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe

36 and younger with laboratory-confirmed Ebola virus disease admitted to EMCs between June and December

37 t focus has been on the recognition of Ebola virus disease among travelers from West Africa, cases of

38 manifestations and adverse outcomes of Zika virus disease among travelers infected in the Americas a

39 manifestations and adverse outcomes of Zika virus disease among travelers infected in the Americas a

40 or use of post-exposure prophylaxis in Ebola virus disease and identify the priorities for future pre

41 98) and age-matched patients with acute Zika virus disease and no neurological symptoms (control grou

42 o decrease the risk of transmission of Ebola virus disease and report pilot data demonstrating no det

43 cination platform in a rodent model of Ebola virus disease and that GP1 N-glycan loss does not influe

44 ty did not differ between survivors of Ebola virus disease and the general population.

45 e information about the pathogenesis of Zika virus disease and the mechanism by which candidate preve

46 was high in people who recovered from Ebola virus disease and were discharged from Ebola treatment u

47 (IHNV) as a model to study aquatic enveloped virus diseases and their inhibition.

48 re and symptoms of sexually transmitted Zika virus disease, and results of semen testing for Zika vir

49 mong children with postnatally acquired Zika virus disease are not well characterized.

50 cohort study, consecutive survivors of Ebola virus disease attending Kerry Town survivor clinic (Free

51 The largest outbreak of Ebola virus disease began in Gueckedou, Guinea, West Africa, i

52 ed by recognizing the fascinating puzzles of virus diseases, being in good places at the right time,

53 , most assays used in the detection of Ebola virus disease by more than 44 diagnostic laboratories yi

54 ll 28 patients who tested positive for Ebola virus disease by RT-PCR were also positive by fingerstic

55 Prevention of virus disease by vaccination or antiviral agents is diff

56 Severe respiratory syncytial virus disease can be prevented by passively administered

57 Suspected Ebola virus disease case definitions that rely on history of f

58 A total of 141 pediatric Zika virus disease cases were identified; none experienced ne

59 Zika virus disease cases were included if they met the nation

60 In survivors of Ebola virus disease, clinical sequelae including uveitis, arth

61 tion of health consequences related to Ebola virus disease could improve patient care for survivors a

62 assays and the urgent need for a rapid Ebola virus disease diagnosis precluded development of validat

63 oduct could help prevent the spread of Ebola virus disease during outbreaks.

64 Inadequate access to rapid testing for Ebola virus disease during the 2014-to-2016 outbreak led to an

65 arch 2016, the West Africa epidemic of Ebola virus disease (Ebola) had resulted in a total of 28,646

66 In 2014, a major epidemic of human Ebola virus disease emerged in West Africa, where human-to-hum

67 dicator across three time periods: pre-Ebola virus disease epidemic (January, 2013, to February, 2014

68 Case fatality in the west African Ebola virus disease epidemic has been highest in children youn

69 The Ebola virus disease epidemic in West Africa is the largest on

70 Following the Ebola virus disease epidemic in west Africa, there has been in

71 work were delayed for months until the Ebola virus disease epidemic was officially declared an emerge

72 ons (based on the 2013-16 west African Ebola virus disease epidemic).

73 case management in the context of the Ebola-virus-disease epidemic and document the effect of the Eb

74 pidemic and document the effect of the Ebola-virus-disease epidemic on malaria case management.

75 cells from four survivors treated for Ebola virus disease (EVD) 1 or 3 months after discharge from t

76 these factors, to predict the risk of Ebola virus disease (EVD) across time and space.

77 697/1054 children testing negative for Ebola virus disease (EVD) and accompanying caregivers.

78 n the characteristics of patients with Ebola virus disease (EVD) and clinical management of EVD in se

79 lth, trauma, and personal exposures to Ebola virus disease (EVD) and health behaviors in post-conflic

80 l hemorrhagic fevers (VHFs), including Ebola virus disease (EVD) and Lassa fever (LF), highlight the

81 rsonnel (HCP) caring for patients with Ebola virus disease (EVD) are at increased risk for infection

82 Animal models recapitulating human Ebola virus disease (EVD) are critical for insights into virus

83 5-year-old boy received a diagnosis of Ebola virus disease (EVD) at the John F.

84 e current West African outbreak of the Ebola virus disease (EVD) began in Guinea in December 2013 and

85 An epidemic of Ebola virus disease (EVD) beginning in 2013 has claimed an est

86 occurrence of previously undocumented Ebola virus disease (EVD) cases and infections, and to reconst

87 From 2014 to May 2015, >26 000 Ebola virus disease (EVD) cases were reported from West Africa

88 ned dramatically, sporadic clusters of Ebola virus disease (EVD) continue well beyond the double incu

89 Thousands of people have survived Ebola virus disease (EVD) during the ongoing outbreak.

90 we developed a compartmental model for Ebola virus disease (EVD) dynamics, which includes three diffe

91 The magnitude of the 2013-2016 Ebola virus disease (EVD) epidemic enabled an unprecedented nu

92 The Ebola virus disease (EVD) epidemic has threatened access to ba

93 Throughout the Ebola virus disease (EVD) epidemic in West Africa, field labor

94 To combat the 2014-2015 Ebola virus disease (EVD) epidemic in West Africa, the World H

95 During the Ebola virus disease (EVD) epidemic in Western Africa (2013-201

96 The 2013-2016 West African Ebola virus disease (EVD) epidemic is the largest recorded.

97 The 2014-15 Ebola virus disease (EVD) epidemic strained health systems in

98 The west Africa Ebola virus disease (EVD) epidemic was extraordinary in scale.

99 e lacking on pregnancy outcomes during Ebola virus disease (EVD) epidemics.

100 Sierra Leone has the most cases of Ebola virus disease (EVD) ever reported.

101 sticks of patients suspected of having Ebola virus disease (EVD) for field diagnostics during an outb

102 ans to manage a patient with confirmed Ebola virus disease (EVD) for the full duration of illness and

103 m the 2013-16 west African outbreak of Ebola virus disease (EVD) has raised several new issues: long-

104 several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and

105 Clinical sequelae of Ebola virus disease (EVD) have not been described more than 3

106 Recent models of Ebola Virus Disease (EVD) have often made assumptions about ho

107 ent center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients.

108 nical and virologic characteristics of Ebola virus disease (EVD) in children have not been thoroughly

109 Ebola virus disease (EVD) in health workers (HWs) has been a m

110 didates.IMPORTANCE The pathogenesis of Ebola virus disease (EVD) in humans is complex, and the mechan

111 impairment in a cohort of survivors of Ebola virus disease (EVD) in Monrovia, Liberia.

112 In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the Wo

113 scent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predominant

114 y being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Co

115 presenting with a late reactivation of Ebola virus disease (EVD) in the UK.

116 presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom.

117 As the outbreak of Ebola virus disease (EVD) in West Africa is now contained, att

118 emen of a large number of survivors of Ebola virus disease (EVD) in Western Africa may contribute to

119 The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatl

120 aracterize epidemiological patterns of Ebola virus disease (EVD) infections during the West African 2

121 Ebola virus disease (EVD) is a contagious, severe and often le

122 Ebola virus disease (EVD) is a highly lethal condition for whi

123 Ebola virus disease (EVD) is a serious illness with mortality

124 Ebola virus disease (EVD) is a severe and frequently lethal di

125 Ebola virus disease (EVD) is a severe viral illness caused by

126 The pathogenesis of human Ebola virus disease (EVD) is complex.

127 apid, accurate, and early diagnosis of Ebola virus disease (EVD) is critical to public health contain

128 (EBOV), but the role of APCs in human Ebola virus disease (EVD) is not known.

129 Several patients with Ebola virus disease (EVD) managed in the United States have re

130 The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple in

131 The 2018 Ebola virus disease (EVD) outbreak in Equateur Province, Democ

132 The worst Ebola virus disease (EVD) outbreak in history has resulted in

133 c information at the start of the 2018 Ebola virus disease (EVD) outbreak in North Kivu Province.

134 The Ebola virus disease (EVD) outbreak in West Africa between 2014

135 , all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had been sto

136 int-of-care instruments in the ongoing Ebola virus disease (EVD) outbreak in West Africa would have d

137 Despite the magnitude of the Ebola virus disease (EVD) outbreak in West Africa, there is st

138 The 2013-present Western African Ebola virus disease (EVD) outbreak is the largest ever recorde

139 The West African Ebola virus disease (EVD) outbreak was the largest EVD outbrea

140 of the Congo (DRC) recorded its eighth Ebola virus disease (EVD) outbreak, approximately 3 years afte

141 e late phase of the large West-African Ebola virus disease (EVD) outbreak, the majority of patients w

142 uted to the sizable toll of the recent Ebola virus disease (EVD) outbreak.

143 The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an international response t

144 The pathogenesis of Ebola virus disease (EVD) remains unclear.

145 persistence in asymptomatic humans and Ebola virus disease (EVD) sequelae have emerged as significant

146 We report on an Ebola virus disease (EVD) survivor who showed Ebola virus in s

147 In this study, serum antibodies from Ebola virus disease (EVD) survivors from Sierra Leone were pro

148 nfectious EBOV in semen specimens of 5 Ebola virus disease (EVD) survivors.

149 ditory, and visual complications among Ebola virus disease (EVD) survivors.

150 ditory, and visual complications among Ebola Virus Disease (EVD) survivors; however, little is known

151 unparalleled West African outbreak of Ebola virus disease (EVD) that began in late 2013, the lack of

152 quently become the largest epidemic of Ebola virus disease (EVD) to date.

153 trials and used to treat patients with Ebola virus disease (EVD) toward the end of the epidemic.

154 (EMLab) consortium was deployed to the Ebola virus disease (EVD) treatment unit in Gueckedou, Guinea,

155 Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature

156 ty and efficacy of vaccines to prevent Ebola virus disease (EVD) were unknown when the incidence of E

157 ious it could explain re-emergences of Ebola virus disease (EVD) without known contact.

158 Ebola virus disease (EVD), a severe viral hemorrhagic fever sy

159 as been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in huma

160 een deforestation and the emergence of Ebola virus disease (EVD), however, is still missing.

161 For highly contagious diseases such as Ebola virus disease (EVD), interpersonal contact plays the mos

162 than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific communit

163 ce of subclinical and paucisymptomatic Ebola Virus Disease (EVD), the prevalence and associated risk

164 Zaire ebolavirus (EBOV) causes Ebola virus disease (EVD), which carries a fatality rate betwe

165 ontributor to outcome in patients with Ebola virus disease (EVD), with high values leading to a fatal

166 frequently recommended intervention in Ebola virus disease (EVD), yet its impact on patient outcomes

167 , that is produced in abundance during Ebola virus disease (EVD).

168 semen of men after their recovery from Ebola virus disease (EVD).

169 s of clinical sequelae in survivors of Ebola virus disease (EVD).

170 a promising immune-based treatment for Ebola virus disease (EVD).

171 sist in the semen of male survivors of Ebola Virus Disease (EVD).

172 ngle-stranded RNA virus that can cause Ebola virus disease (EVD).

173 sponse workers with suspected or known Ebola virus disease (EVD).

174 collected from persons diagnosed with Ebola virus disease (EVD).

175 ntive behaviours during an outbreak of Ebola virus disease (EVD).

176 s a promising therapeutic approach for Ebola virus disease (EVD).

177 ems have been reported in survivors of Ebola virus disease (EVD).

178 re key components to prevent and treat Ebola virus disease (EVD).

179 f virus replication, viremia and fatal Ebola virus disease (EVD).

180 history of fever and risk factors for Ebola virus disease exposure do not have sufficient sensitivit

181 ccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine eff

182 neral Guinean population, survivors of Ebola virus disease had a more than five-times increased risk

183 However, recent work in a variety of virus diseases has highlighted the importance of couplin

184 international responders, few cases of Ebola virus disease have been diagnosed in this group.

185 The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an

186 We regarded samples to be positive for Ebola virus disease if the cycle threshold was 40 or lower.

187 gans contributes to the development of Ebola virus disease.IMPORTANCE Ebola virus (EBOV) remains a hi

188 is a promising vaccine candidate for Marburg virus disease.IMPORTANCE Marburg virus (MARV) is a virus

189 ytokine response that is a hallmark of Ebola virus disease.IMPORTANCE Understanding how the host resp

190 the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of re

191 ary analysis compared the incidence of Ebola virus disease in eligible and vaccinated individuals ass

192 protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in

193 oms observed in acute and convalescent Ebola virus disease in human patients.

194 Ebola virus disease in humans is highly lethal, with case fata

195 t of remdesivir for the treatment of Marburg virus disease in humans.

196 pecies in the genus are known to cause Ebola Virus Disease in humans.

197 In 1976, the first cases of Ebola virus disease in northern Democratic Republic of the Con

198 describe clinicopathologic features of Ebola virus disease in pregnancy.

199 vided no benefit for the prevention of Ebola virus disease in rhesus macaques with regards to reducti

200 alence and severity of respiratory syncytial virus disease in the first few weeks of life, whereas ma

201 ical manifestations and epidemiology of Zika virus disease in travelers exposed in the Americas.

202 ical manifestations and epidemiology of Zika virus disease in travelers exposed in the Americas.

203 term reduction in risk of symptomatic dengue virus disease in vaccinees.

204 The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016 resul

205 The recent epidemic of Ebola virus disease in West Africa resulted in an unprecedente

206 The 2013-2016 epidemic of Ebola virus disease in West Africa was of unprecedented magnit

207 During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therap

208 CT]) for all contacts of patients with Ebola virus disease (in terms of administration and averted ET

209 For an SWCT, regional variation in Ebola virus disease incidence trends produced increased false-

210 the provision of care to patients with Ebola virus disease, including absence of pre-existing isolati

211 nonhuman primates against all signs of Ebola virus disease, including viremia.

212 and June 16, 2015, of 151 survivors of Ebola virus disease invited to participate, 112 (74%) provided

213 Ebola virus disease is a serious illness of humans and nonhuma

214 Ebola virus disease is associated with a high prevalence of ha

215 Providing RRT in Ebola virus disease is complex and requires meticulous attenti

216 report supports previous findings that Zika virus disease is generally mild in children.

217 n Sierra Leone, where the incidence of Ebola virus disease is spatiotemporally heterogeneous, and is

218 ica, Crimean-Congo haemorrhagic fever, Ebola virus disease, Lassa fever, and Marburg virus disease.

219 the mechanisms of evolution is important for virus disease management and controlling the emergence o

220 o-friendly strategies is required to advance virus disease management in diverse agricultural croppin

221 showed therapeutic efficacy in this Marburg virus disease model with treatment initiation 5 days pos

222 n medically evacuated for treatment of Ebola virus disease, more commonly they were evacuated after p

223 Maize streak virus disease (MSVD), caused by Maize streak virus (MSV;

224 causes sporadic outbreaks of severe Marburg virus disease (MVD).

225 identified in a human survivor of Bundibugyo virus disease, neutralizes both Bundibugyo virus and Ebo

226 l 117 clusters showed that no cases of Ebola virus disease occurred 10 days or more after randomisati

227 No cases of Ebola virus disease occurred 10 days or more after randomisati

228 No secondary cases of Ebola virus disease occurred among the vaccinees.

229 n could largely mitigate the effect of Ebola virus disease on malaria.

230 sought to quantify the consequences of Ebola virus disease on maternal and child health services in t

231 tors significantly declined during the Ebola virus disease outbreak in 2014.

232 During the ongoing Ebola virus disease outbreak in parts of Western Africa, most

233 The Ebola virus disease outbreak in west Africa has prompted signi

234 After the detection of an Ebola virus disease outbreak in west Africa in 2014, one of th

235 The Ebola virus disease outbreak in west Africa is pivotal for the

236 The 2013-16 Ebola virus disease outbreak in west Africa was associated wit

237 The magnitude of the 2013-2016 Ebola virus disease outbreak in West Africa was unprecedented,

238 at a human survivor of the 1995 Kikwit Ebola virus disease outbreak maintained circulating antibodies

239 In the post-Ebola virus disease outbreak period, vaccination coverage for

240 Compared with pre-Ebola virus disease outbreak trends, significant decreases occ

241 In the months before the Ebola virus disease outbreak, all three maternal indicators sh

242 geting EBOV.IMPORTANCE The most recent Ebola virus disease outbreak, from 2014 to 2016, resulted in a

243 been historically used to investigate Ebola virus disease outbreaks and how new technologies allow f

244 ublic health officials when addressing Ebola virus disease outbreaks in countries and seasons where m

245 ly implemented at scale in response to Ebola virus disease outbreaks in rural settings.

246 tion that has been applied to Ebola and Zika virus disease outbreaks, among others, and is currently

247 In 49 patients with known Ebola virus disease outcomes during the ongoing outbreak in Si

248 escription of the clinical features of Ebola virus disease over the duration of illness in children a

249 r safe and effective vaccines against dengue virus disease, particularly for individuals who are deng

250 Our knowledge relating to the virus, disease pathogenesis, risk factors, dynamics of t

251 critical role for the delta peptide in Ebola virus disease pathology and as a possible target for nov

252 t may be a novel, targetable aspect of Ebola virus disease pathology.IMPORTANCE During the unparallel

253 pment (PPE) during care activities for Ebola virus disease patients has not yet been characterized.

254 The 2014 west African epidemic of Ebola virus disease posed a major threat to the health systems

255 Ebola virus disease poses a global health threat.

256 ative agent of the largest outbreak of Ebola Virus Disease recorded.

257 ted positive 12 months or longer after Ebola virus disease recovery.

258 dengue, chikungunya, yellow fever, and Zika virus disease) resulting from the triad of the modern wo

259 e, or clinically suspected diagnosis of Zika virus disease seen between January 2013 and 29 February

260 e, or clinically suspected diagnosis of Zika virus disease seen between January 2013 and 29 February

261 Influenza virus disease severity is influenced by viral virulence

262 treatment to contacts of patients with Ebola virus disease should be considered by public health offi

263 ure in late deaths after recovery from Ebola virus disease should be investigated.

264 has experienced the most outbreaks of Ebola virus disease since the virus' discovery in 1976.

265 for management of whiteflies to reduce plant virus disease spread.

266 la virus has been detected in semen of Ebola virus disease survivors after recovery.

267 As of May 6, 2016, 466 Ebola virus disease survivors had enrolled in the programme; r

268 Health Screening Program (MHSP) offers Ebola virus disease survivors semen testing for Ebola virus.

269 's Health Screening Program helps male Ebola virus disease survivors understand their individual risk

270 virus, despite never having developed Ebola virus disease symptoms, highlighting an important and po

271 most commonly reported symptom of post-Ebola virus disease syndrome in survivors is arthralgia, yet i

272 The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 1

273 y and clinical data from patients with Ebola virus disease to better inform clinical management algor

274 tment to all contacts of patients with Ebola virus disease, to prevent the onset of febrile malaria a

275 n of ACTs to contacts of patients with Ebola virus disease was cost saving for contacts of all ages i

276 , the characteristic histopathology of Ebola virus disease was not observed, and this absence of seve

277 In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ri

278 After confirmation of a case of Ebola virus disease, we definitively enumerated on a list a ri

279 m optimal care in a future outbreak of Ebola virus disease, we employed the Grading of Recommendation

280 c 8, 2014, 850 patients with suspected Ebola virus disease were admitted to the holding unit, of whom

281 gust 2016, 256343 specimens tested for Ebola virus disease were captured in the database.

282 No new cases of Ebola virus disease were diagnosed in vaccinees from the immed

283 ults: Starting in May 2015, 93 cases of Zika virus disease were reported.

284 ated serious adverse events or severe dengue virus disease were reported.

285 Starting in May 2015, 93 cases of Zika virus disease were reported.

286 efit could be obtained.Twelve cases of Nipah virus disease were treated in the emergency department o

287 rVSVDeltaG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 x 107 plaque-forming units

288 Patients recovering from Ebola virus disease who do not meet the case definition for ac

289 to gain information about survivors of Ebola virus disease who subsequently died from their closest f

290 contact and follow-up all survivors of Ebola virus disease who were discharged from Ebola treatment u

291 Of the 1270 survivors of Ebola virus disease who were discharged from Ebola treatment u

292 ributed to our better understanding of Ebola virus disease with a paper underlying the crucial role o

293 atient who had been treated for severe Ebola virus disease with high viral load (peak cycle threshold

294 ome was a laboratory confirmed case of Ebola virus disease with onset 10 days or more from randomisat

295 cination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after

296 offers substantial protection against Ebola virus disease, with no cases among vaccinated individual

297 offers substantial protection against Ebola virus disease, with no cases among vaccinated individual

298 ed surveillance systems for symptomatic Zika virus disease (ZVD) and birth defects provided complemen

299 olombia began official surveillance for Zika virus disease (ZVD) in August 2015.

300 olombia began official surveillance for Zika virus disease (ZVD) in August 2015.